Skip to content
Wenlo
Sign in
← Markets

Neurocrine Biosciences, Inc.

Eiry Roberts (Chief Medical Officer) reports NBIX insider transactions

4NBIXFiled Nov 5, 2026, 11:10 AM ET· Period Nov 4, 2026

About this filing

Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 5, 2026. Form 4 reports a company insider’s trades in the company’s shares.

Key facts

Insider
Eiry Roberts · Chief Medical Officer
DateTransactionSharesPriceValueHeld afterOwnership
Nov 4, 2026A · grantStock OptionFootnotes F1+8,314$0.00$0.008,314Direct
Nov 4, 2026A · grantRestricted Stock UnitFootnotes F2, F3+1,506$0.00$0.001,506Direct
Footnotes
  1. F1 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
  2. F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  3. F3 The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.

More NBIX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.